Scientists test new drug duo to boost lung cancer treatment
NCT ID NCT04895579
Summary
This small, early-stage study tested whether adding a new drug called copanlisib to an existing immunotherapy (durvalumab) could help patients with a specific type of advanced lung cancer. The main goal was to find a safe dose for the drug combination and see if it could help the immune system fight the cancer more effectively. The study involved 11 patients whose cancer could not be removed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.